Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
Apply
Pembrolizumab & Lenvatinib
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step